About: Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes
Creator	Cheong, Hee Kang, Seong Kim, Woo Noh, Ji Song, Joon Choi, Min Ho Jeon, Ji Jung, Eun
Source	Elsevier; Medline; PMC
abstract	Early diagnosis of pneumococcal pneumonia facilitates appropriate antibiotic therapy. The urinary antigen test (UAT) is known to be useful for the diagnosis of pneumococcal pneumonia. This study aimed to evaluate the usefulness of UAT in the 13-valent pneumococcal conjugated vaccine (PCV13) era. Community-acquired pneumonia (CAP) cases aged ≥19 years were reviewed retrospectively. This study evaluated the utility of Streptococcus pneumoniae UAT (BinaxNOW(®) assay) for diagnosis of pneumococcal CAP, and the relation of the UAT positive rate to age, comorbidities, pneumonia severity, and pneumococcal serotypes. Among 752 microbiologically identified CAP cases, S. pneumoniae (36.7%) was the most common isolate, and of those cases, 56.4% were positive for UAT. UAT positivity varied by pneumococcal serotype (serotype 3, 50%; 9V/9A, 85%; 11A/11E, 54%; 14, 36.4%; 19A, 50%; and 23F, 37.5%), and was significantly increased since 2012, two years after introduction of PCV13. The positive rate of UAT was significantly related to CRP level (P = 0.007) and lobar pneumonia (P = 0.006), but not to age, co-morbidities or prior antibiotic therapy. In conclusion, urinary antigen detection varied depending on the S. pneumoniae serotype. In the PCV13 era, the serotype distribution of pneumococcal pneumonia may be changing, and the clinical usefulness of UAT needs to be monitored. The positive rate of UAT may be influenced by a localized bacterial burden and host reactions.
has issue date	2015-06-19(xsd:dateTime)
bibo:doi	10.1016/j.jiac.2015.06.003
bibo:pmid	26212866
has license	no-cc
sha1sum (hex)	924b87047028e1e55df1b901323bd03fb19e7d3b
schema:url	https://doi.org/10.1016/j.jiac.2015.06.003
resource representing a document's title	Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes
has PubMed Central identifier	PMC7128949
has PubMed identifier	26212866
schema:publication	J Infect Chemother
resource representing a document's body	covid:924b87047028e1e55df1b901323bd03fb19e7d3b#body_text
is schema:about of	named entity 'positive' named entity 'serotype' named entity 'diagnosis' named entity 'antigen test' named entity 'STRATIFIED' named entity 'LEVEL' named entity 'NEEDS' named entity 'ANTIGEN DETECTION' named entity '19A' named entity 'LOBAR PNEUMONIA' named entity 'PNEUMONIA' named entity 'POSITIVE FOR' named entity 'SEROTYPE' named entity 'HOST' named entity 'INCREASED' named entity 'COMMON' named entity 'YEARS' named entity 'USEFULNESS' named entity 'REVIEWED' named entity 'PNEUMOCOCCAL' named entity 'STREPTOCOCCUS PNEUMONIAE' named entity 'DIAGNOSIS' named entity 'CONCLUSION' named entity 'URINARY ANTIGEN' named entity '50%' named entity 'IDENTIFIED' named entity 'ISOLATE' named entity 'ANTIBIOTIC THERAPY' named entity 'URINARY ANTIGEN TEST' named entity '11A' named entity 'SEROTYPES' named entity 'PCV13' named entity 'DISEASE SEVERITY' named entity 'AGE' named entity 'CLINICAL USEFULNESS' named entity 'FOR DIAGNOSIS' named entity 'RELATION' named entity 'CASES' named entity 'STUDY' named entity 'CAP' named entity '752' named entity 'BUT' named entity 'ASSAY' named entity 'RELATED' named entity 'UTILITY' named entity 'CONJUGATED VACCINE' named entity 'SEROTYPES' named entity 'SEVERITY' named entity 'AGED' named entity 'URINARY ANTIGEN TEST' named entity 'EVALUATE' named entity 'DISTRIBUTION' named entity 'COMORBIDITIES' named entity 'PNEUMOCOCCAL PNEUMONIA' named entity 'BACTERIAL' named entity 'PRIOR' named entity 'KNOWN' named entity 'APPROPRIATE' named entity '28P' named entity 'CRP' named entity '37.5' named entity 'INTRODUCTION' named entity 'CHANGING' named entity 'REACTIONS' named entity 'MAY BE' named entity 'EARLY DIAGNOSIS' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'LOCALIZED' named entity 'POSITIVE RATE' named entity 'MONITORED' named entity 'USEFUL' named entity 'PNEUMOCOCCAL' named entity 'CLINICAL USEFULNESS' named entity 'BURDEN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software